肿瘤细胞治疗研究
FRONTIER PAPERS
Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Co
在这一随访时间相对较短的真实世界数据集中，与其他全身性抗肿瘤治疗相比，多发性骨髓瘤患者在接受 CAR-T 治疗后似乎具有更高的血液系统第二原发恶性肿瘤风险。
Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.
患者（N = 84）中位接受过 5 线既往治疗，49% 既往接受过 B 细胞成熟抗原靶向治疗。
How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies.
T细胞衔接双特异性抗体（BsAbs）已改变了多种血液系统恶性肿瘤的治疗格局，目前正在一线治疗、联合方案以及非恶性疾病中开展研究。
Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis.
在真实世界实践中，接受 T 细胞重定向治疗的 RRMM 患者中约每 4 例就有 1 例发生严重感染。
CAR-T therapy moving to first-line in multiple myeloma: latest updates from the 2025 ASH annual meeting.
这些数据支持MM治疗模式的转变，即更早地整合CAR-T疗法。
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study.
5例经多线治疗的男性患者（中位既往治疗线数为3线）被连续入组，并接受中位6.0个月的随访。
CAR-T cell therapy for pediatric solid tumors: armored CAR-T cells and beyond.
CAR-T 细胞疗法利用经工程化改造以靶向特定肿瘤抗原的自体 T 细胞，是近年来儿童和成人血液系统恶性肿瘤治疗中最具前景的进展之一。
A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy.
这些发现强调了免疫年龄作为一个临床相关的复合指标，比实际年龄更能反映患者的免疫状态。
BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study.
CAR-T 细胞疗法尚未在老年新诊断多发性骨髓瘤（NDMM）患者中常规开展研究，因此我们评估了 AZD0120 作为 70 岁 MM 患者一线治疗的效果。
Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of
随着 CD38 靶向抗体的引入，老年多发性骨髓瘤 (MM) 患者的治疗格局已迅速演变。
MEMBER ACCOUNT
登录成功会直接打开下一页。
